Abstract
This study underscores the possibility of the pharmacologic modulation of the ARID1A factor to downregulate protumorigenic IGF-1 activity in patients with postmenopausal breast cancer undergoing aromatase inhibitor treatment.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have